Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumour microenvironment.In June 2023, Surface Oncology entered into a definitive merger agreement to be acquired by Coherus BioSciences Inc.In April 2018, the company priced its initial public offering of 7,200,000 shares of common stock at a public offering price of $15.00 per share. The company granted the underwriters a 30-day option to purchase up to 1,080,000 additional shares of common stock at the initial public offering price, less the underwriting discount. The gross proceeds from the offering, were expected to be $108.0 million. Surface's common stock began trading on the Nasdaq Global Market under the ticker symbol "SURF" on April 19, 2018. In addition to the shares sold in the public offering, Surface announced the concurrent sale of an additional 766,666 shares at the initial offering price of $15.00 per share, for gross proceeds of $11.5 million, in a private placement to Nov